Introduction: Unresectable, well-differentiated nonfunctioning gastroenteropancreatic neuroendocrine tumors (GEP-NETs) can be monitored (watchful waiting, WW) or treated with systemic therapy such as somatostatin analogues (SSAs) to delay progression. We applied a reflective multicriteria decision analysis (MCDA) shared-decision framework (previously developed for the USA) to explore what matters to Spanish patients and clinicians considering GEP-NET treatment options.
INTRODUCTION
Nonfunctioning gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are slow-growing tumors with non-specific symptoms, which may lead to erroneous or delayed diagnosis [1] . Up to 60% of these tumors have already metastasized at the time of diagnosis [2] . In Europe, the prevalence of well-differentiated, nonfunctioning, neuroendocrine tumors of the pancreas and digestive organs is estimated to be 13 per 100,000 [3] . In the Spanish National Cancer Registry for Gastroenteropancreatic Neuroendocrine Tumors, 887 patients were registered from June 2001 through December 2008 [4] . Median survival among these patients exceeded 12 years, and the estimated 5-year relative survival was 78.1% for GEP-NETs of pancreatic and 80.4% for GEP-NETs of gastrointestinal (GI) origin [4] .
According to the Sociedad Española de Oncología Médica [5] , for patients with unresectable, advanced or metastatic, well-differentiated NETs, management options depend on tumor grade:
• For grade 1 disease (proliferative index, Ki67 B 2%) observation with computed tomography (CT) scans every 3-6 months is recommended and somatostatin analogue (SSA) therapy (lanreotide or octreotide) may be considered if the octreoscan is positive.
• For grade 2 disease (Ki67 = 3-20%) or in patients with significant tumor burden, or in case of disease progression, SSA therapy (lanreotide or octreotide) is recommended if the octreoscan is positive and the proliferative index (Ki67) is below 10%. Other options include interferon, if SSA therapy fails; targeted agents (everolimus or sunitinib); chemotherapy if Ki67 [ 10%; clinical trials; and peptide receptor radionucleotide therapy, if available. More generally, the European Neuroendocrine Tumor Society Consensus Guidelines [6] state that SSAs may be used in stable or progressive disease or in patients with unknown tumor behavior. SSAs are recommended as firstline therapy in midgut, intestinal, and pancreatic NETs to control tumor growth.
These recommendations are primarily based on two double-blind clinical trials. In the multicenter PROMID study, 85 patients with welldifferentiated, metastatic, midgut NETs were randomized to 30 mg octreotide LAR (long-acting formulation) monthly via intramuscular injection or matching placebo. Octreotide LAR significantly improved time to progression when compared with placebo [median 14.3 vs 6 months; hazard ratio (HR) 0.34; 95% confidence interval (CI), 0.20-0.59; P = 0.000072]. After 6 months of treatment, 66.7% of patients in the octreotide LAR group had stable disease compared to 37.2% in the placebo group [7] . In the multinational CLARINET study, 205 patients with advanced, well-or moderately differentiated, nonfunctioning GEP-NET were randomized to lanreotide 120 mg via deep subcutaneous injection every 28 days or placebo. Lanreotide significantly improved progressionfree survival (PFS) when compared with placebo (median not reached vs 18.0 months; HR 0.47; 95% CI 0.30-0.73, P \ 0.001) [8] .
The guidelines above leave it open as to whether SSA therapy should be started at initial diagnosis of unresectable disease or after observation of the spontaneous tumor growth and initiated when disease progression occurs [6] . In such circumstances, in addition to the intervention's potential risks and benefits, factors such as the impact of the disease, personal costs, and constraints as well as individual values and preferences would play a role in treatment decisions and should be discussed between patients and physicians. The right to patient autonomy is recognized by Spanish law [9] and several initiatives have been launched in Spain to empower patients to actively participate in healthcare decisions [9, 10] . In a recent survey, the majority of Spanish cancer patients preferred a shared approach to decision-making, but only about half of them reported that this is what they actually experienced in practice [11] , indicating a need to further develop approaches to support patient involvement.
In a previous study conducted in the USA, a framework to support shared decision-making for GEP-NET management had been designed on the basis of the open-source, multicriteria decision analysis (MCDA) EVIDEM framework [12] . The framework, in which the available evidence for GEP-NET management options was embedded, enabled patients and clinicians to identify what mattered to them in their individual decision-making context and share their diverse perspectives, thus supporting individual reflection and patient-clinician communication. In the current study, the framework was applied in the Spanish context with the objectives of validating the applicability of the approach across countries as well as exploring the preferences and underlying criteria that Spanish patients and clinicians use when considering and making their decisions on the treatment options for unresectable, well-or moderately differentiated, locally advanced or metastatic nonfunctioning GEP-NET.
METHODS
The study involved adaptation of the previously designed MCDA-based decision support framework for unresectable, well-differentiated, locally advanced or metastatic nonfunctioning GEP-NET to the Spanish context and its application to a group of Spanish patients and clinicians in a decision support workshop. The framework is designed in two modules: [12] the first allows one to derive a benefit-risk balance based solely on intervention outcomes (''core benefit-risk criteria'', including comparative efficacy/effectiveness, comparative patient-perceived health/patient-reported outcomes, and comparative safety/tolerability), organized in the core benefit-risk tree. The second contains, in addition to the three core criteria, other decision-making factors that may modulate the benefit-risk balance (modulating criteria, organized in the modulated benefit-risk tree) (see Supp. Appendix A for full list of criteria and subcriteria and their definitions). The primary decision scenario, defined on the basis of Spanish and European clinical practice guidelines, explored whether to start SSA therapy (using lanreotide as reference case) or to monitor the disease (watchful waiting); a second scenario explored the choice between two SSA therapies, lanreotide and octreotide.
Evidence on GEP-NET and Management Options: MCDA Evidence Matrices An evidence matrix was created following EVI-DEM's targeted systematic literature review methodology and data synthesis approach as reported previously [12, 13] . It was updated and adapted to the Spanish context, and translated into Spanish. Briefly, relevant evidence was retrieved from the biomedical literature databases (PubMed/Medline), Cochrane systematic reviews, clinical trial registries, conferences, bibliographies of pertinent publications, and patient and professional association websites (as well as other gray literature and proprietary data, as applicable). Clinical data were validated by a Spanish clinical GEP-NET expert. The evidence matrices included a total of 36 references.
Decision Support Workshop
Both patients and clinicians were invited to participate in the decision support workshop as experts in decision-making on the disease, following predefined recruitment criteria (Supp. Appendix B). Patients-adults with locally advanced or metastatic nonfunctioning (asymptomatic) GEP-NET receiving SSA treatment or under watchful waiting-were recruited through the local patient organization. Clinicians had to be active practitioners (oncologist or endocrinologist) specialized in treating patients with locally advanced or metastatic GEP-NET. In order to capture potential variations in practice and healthcare delivery, patients and clinicians were recruited from different regions of Spain. Study investigators first introduced the approach and decision criteria definitions (provided in Supp. Appendix 2). Then participants individually weighted the relative importance of the criteria on the basis of what mattered most and least to them when making a decision on the management options for unresectable, well-differentiated nonfunctioning GEP-NET. Participants applied two weighting methods: first, they distributed 100 weighting points across the domains, criteria, and subcriteria of the benefit-risk trees (hierarchical point allocation, HPA [15] ); these weights were used for the primary analysis. Then, they rated the relative importance of each (sub)criterion on a scale from 1 to 5 (direct rating scale, DRS); the weights derived from this method were used in an alternative analysis [16] .
Weighting was followed by a stepwise exploration of primary decision scenario on the basis of the evidence matrix: the evidence for a criterion was presented by study investigators, the group exchanged their views and comments, and then each participant expressed individually how consideration of the criterion would impact his/her decision by assigning a score on a constructed, cardinal scale ranging from ? 5 (''Much in favor of option 1'') to -5 (''Much in favor of option 2''). Participants also recorded individual insights and needs for additional information in writing. For qualitative criteria, participants specified the type of impact on the decision (positive, no or negative impact). The same steps were followed to explore the second scenario. Participants provided their feedback on the process in a structured discussion at the completion of the workshop or in written form. Two weeks after the workshop, participants received the results of their own assessments and were asked to comment on whether these reflected their reasoning during the exercise (face validity).
Data Analysis
Data was analyzed as reported previously [12, 17] . Briefly, for both weighting methods, crude weights were normalized to sum up to 1.0 across all subcriteria and criteria of the core and modulated benefit-risk tree, respectively. Relative benefit-risk balances (RBRB) and modulated RBRBs were calculated following a linear additive model as the sums of the products of the normalized weights and standardized scores (= score/5). RBRBs can range in theory from -1 to ? 1.
To examine the impact of the weighting technique, the mean RBRBs, incorporating weights from the two weighting techniques, were compared. In addition, the proportions of participants for whom these RBRBs differed by more than 0.1 and by more than 0.05 points (corresponding to 5% and 2.5% of the total RBRB range) were determined.
Numerical outputs were calculated for individual participants and then combined into mean group values. Variability was quantified using standard deviations (SD). Written and verbal comments were organized and summarized by criteria. Exploratory analyses were performed to compare patient and clinician subgroups as well as to compare quantitative outcomes of the current and the US study, which followed a similar design and included the same number of patients and clinicians.
RESULTS
Five patients and six clinicians from different regions of Spain participated in the decision support workshop.
Clarifying Values and Preferences: Criteria Weights
Using hierarchical point allocation, the majority of participants assigned a non-zero weight to all criteria and subcriteria of the benefit-risk and the modulated benefit-risk tree, with the exception of level of chromogranin A and size of the affected population, both of which received a 0 weight from 7 of the 11 participants.
Distributing weights across the core benefit-risk tree (intervention outcomes), participants assigned the highest weight to impact on health-related quality of life (HRQoL) (normalized mean ± SD 0.15 ± 0.06), followed by fatal adverse events (0.13 ± 0.06), overall survival (0.12 ± 0.07), progression-free survival (0.12 ± 0.07), and impact on autonomy (0.09 ± 0.05), and the lowest weight to level of chromogranin A (0.01 ± 0.02) (Fig. 1a) . The largest variations in weights were recorded for progression-free survival and overall survival (both SD ± 0.07). Exploratory subgroup analysis indicated that patients assigned the most weight to impact on HRQoL (0.15 ± 0.06), impact on autonomy (0.12 ± 0.06), and fatal adverse events (0.11 ± 0.08), whereas clinicians assigned the most weight to overall survival (0.14 ± 0.07), impact on HRQoL (0.14 ± 0.06), and fatal adverse events (0.14 ± 0.05).
Weighting all criteria (including the modulating), participants allocated the most weight to system capacity and appropriate use and type of therapeutic benefit (normalized mean ± SD 0.14 ± 0.07 for both), followed by comparative effectiveness (0.11 ± 0.05), quality of evidence (0.10 ± 0.08), and disease severity (0.10 ± 0.05) and the least weight to size of affected population (0.01 ± 0.02) and non-medical costs and constraints (0.02 ± 0.01) (Fig. 1b) . Weights varied most for the criteria quality of evidence (SD ± 0.08), type of therapeutic benefit and system capacity and appropriate use (SD ± 0.07 for both). Exploration of subgroups revealed that both patients and clinicians assigned the highest weight to type of therapeutic benefit (0.15 ± 0.06 and 0.13 ± 0.08, respectively) and system capacity and appropriate use (0.14 ± 0.05; 0.15 ± 0.08), followed by patientperceived health/PROs (0.11 ± 0.04) among patients and quality of evidence (0.12 ± 0.09) among clinicians.
Which Option Does Consideration of Each
Criterion Favor? Criteria Scores, Impacts, Comments, and Insights
Exploring how each intervention outcome criterion favors SSA treatment (with lanreotide as a reference case) or watchful waiting, progressionfree survival was clearly considered in favor of treatment, with a mean score of ? 4.5 (scale -5 to ? 5) and little variation among participants (SD ± 0.7) ( Table 1 ). All other outcomes were also scored on the group level in favor of treatment; however, mean scores remained within the range of 0 to ? 1, with the exception of fatal adverse events (? 2.2 ± 2.7), level of chromogranin A (? 1.9 ± 1.9), and impact on HRQoL (? 1.4 ± 1.3). The largest individual variations in scores (SD [ ±2.5) were observed for the comparative safety/tolerability subcriteria as well as for convenience/ease of use/mode and setting of administration and impact on autonomy. In exploratory subgroup analysis, the greatest difference in scores was seen for tumor regression rate (patients ? 2.4 ± 1.8 vs clinicians -0.1 ± 1.0) and for non-fatal nonserious adverse events (-1.2 ± 3.4 vs ? 1.3 ± 2.1).
Among modulating criteria, disease severity and quality of evidence were clearly considered to be in favor of treatment [mean (SD) scores ? 3.8 ± 0.6 and ? 3.8 ± 1.0, respectively], with minor variation among participants and between patient and physician subgroups. Conversely, the greatest variations in scores (SD C ±2.3) were seen for criteria of the domain economic consequences and constraints of intervention. In exploratory subgroup analyses, patients' and clinicians' assessments differed the most for cost of intervention to the healthcare system (patients vs clinicians ? 2.5 ± 1.6 vs -2.1 ± 2.2) and other medical costs and constraints to patient (? 2.4 ± 2.5 vs ? 0.5 ± 2.0).
With respect to the qualitative modulating criteria (data not shown), five of the 11 participants considered that opportunity costs and affordability had an impact in favor of treatment, but one considered it to favor watchful waiting. Four participants considered common goal and specific interests to favor treatment, while three deemed it to favor watchful waiting. For the other qualitative criteria (mandate and scope of the healthcare system, environmental impact, political/historical/cultural context), the majority of participants indicated that these were either not considered or had no impact on their decisionmaking.
Participants commented on the validity and (un)certainty of the clinical, economic, and epidemiological data presented and the potential availability of data from other sources ( Table 1) . They also noted the importance of considering the impact of the treatment on HRQoL, expressed the assumption that slowing disease progression could have a positive impact on HRQoL, and exchanged their insights on the impact of non-serious adverse events, such as diarrhea. The potential challenges and benefits of patient self-administration of lanreotide (i.e., Fig. 1 Mean (SD) normalized weights assigned by 11 participants using hierarchical point allocation to each domain/ criterion/subcriterion of the MCDA a core and b modulated benefit-risk trees • It would also depend iniƟally on the risk of progression of the disease • The data are very robust. Primary endpoint on a registraƟon/pivotal trial • Important to note that the lanreoƟde-placebo benefit raƟo was 2:1 • The OLE study is biased since it only included paƟents who had not progressed with lanreoƟde for 2 years (excluding 48% of paƟents who progressed before being in the CLARINET study) • There is other evidence from Spanish case studies; however, these have much lower validity
Disease symptoms
No data on tumor-related symptoms for either opƟon
• PaƟents have few symptoms, so this parameter is of liƩle importance in this context • A lot of uncertainty with respect to this point. However, clinicians are used to dealing with lack of perfect informaƟon and need to take decisions in daily pracƟce considering different levels of uncertainty • Clinical experience of the physician is also important, independently of the study data • In my clinical experience, there is no evidence indicaƟng a negaƟve effect of lanreoƟde on symptoms related to the disease • Here we should also consider the placebo effect Tumor regression rate
No data for either opƟon
• There are other lower-quality retrospecƟve studies with various tumor regression rates (range 1 to 6%)
• Tumor regression rates of 30% with lanreoƟde have been described in a very low percentage of paƟents. The majority of paƟents do not experience any parƟcular benefit on this criterion
Overall survival CLARINET: [22] No staƟsƟcally significant difference between lanreoƟde and placebo
• Given long survival in NET, 2 years of follow-up is very liƩle and not sufficient to determine survival • The informaƟon provided in the manual is describing a preference-based comparison between selfinjecƟon of lanreoƟde versus aƩending a medical site (and not real differences in autonomy between lanreoƟde vs watchful waiƟng)
Impact on dignity
No data for either opƟon • If we compare it with placebo, not geƫng treatment will always be more "convenient" in terms of posology than any drug • In Spain, lanreoƟde self-administraƟon is not indicated for this condiƟon • From the paƟent perspecƟve, self-administraƟon of lanreoƟde is a bit complicated. However, many paƟents living in small villages would benefit from this form of administraƟon COMPARATIVE SAFETY / TOLERABILITY Non-fatal non-serious adverse events CLARINET: [22] • NA Fatal adverse event CLARINET: [22] No fatal AEs in either arm
• NA • Indolent disease with a high percentage of paƟents presenƟng with metastasis at diagnosis
Unmet needs
Other anƟproliferaƟve treatment opƟons are generally recommended only aŌer failure of SSA therapy. [6] Chemotherapy is an early intervenƟon opƟon for pancreaƟc NET (advanced/ metastaƟc G1-G2 pNETs) [5] .
• There are other anƟ-proliferaƟve opƟons (everolimus, suniƟnib, systemic chemotherapy, pepƟde receptor radionuclide therapy). In general, these alternaƟves are only recommended aŌer treatment with SSAs is considered to have failed
Size of populaƟon
Prevalence in Europe (RARECARE data): 13/100,000 of differenƟated, nonfuncƟoning, endocrine tumor of the pancreas and digesƟve organs [3] • In the Spanish GEN-NET registry, 3,000 paƟents have been included. This is the second largest registry of GEP-NET paƟents in the world • Rarecare registry data might result in an underesƟmaƟon of GEP -NET prevalence in Spain
ECONOMIC CONSEQUENCES AND CONSTRAINTS OF INTERVENTION Cost of intervenƟon to paƟent
LanreoƟde: €55 paƟent co-payment per year [23, 24] Watchful waiƟng: not applicable
• In the Autonomous CommuniƟes and CiƟes, for a drug dispensed by hospitals, the cost for the paƟent is 0. Therefore, the cost to the paƟent is between 0 and 55 €/year
Cost of intervenƟon to the healthcare system LanreoƟde: €10,000-20,000 per year [33, 34] Watchful waiƟng: no data
• Exact price is available • There could be some addiƟonal medical costs for paƟents if they would need to be treated for side effects (i.e., hyperglycemia, diabetes…)
Other medical costs & constraints to the healthcare system LanreoƟde: potenƟal costs & constraints related to AE monitoring and treatments Both lanreoƟde and watchful waiƟng: costs & constraints related to monitoring for disease progression
• The only differences in resources between lanreoƟde and placebo are visits for injecƟon and for management of adverse effects, which being minimum, is of liƩle impact
Non-medical costs and constraints
No data for either opƟon [29] Watchful waiƟng: usual standard of care (regular tests and scans)
• NA AE adverse event, CI confidence interval, ENETS European Neuroendocrine Tumor Society, HR hazard ratio, HRQoL health-related quality of life, NA not available (no comments provided), OLE open-label extension, QoL quality of life, RCT randomized clinical trial, SEOM Sociedad Española de Oncología Médica, SSA somatostatin analogue difficult to self-administer but useful for remote populations) were also highlighted.
Combining Weights and Scores to Derive the Overall Relative Benefit-Risk Balance
At the group level, the mean RBRB (linear combination of weighted scores across all core benefit-risk subcriteria) favored treatment over watchful waiting (? 0.32 ± 0.24, scale -1 to ? 1), but with wide individual variations across the 11 participants (? 0.05 to ? 0.64). In exploratory analysis, the RBRB favored treatment among both patients and physicians (? 0.25 ± 0.27 vs ? 0.39 ± 0.21). Progressionfree survival made the highest contribution to the mean RBRB (? 0.11 ± 0.07), followed by fatal adverse events (? 0.06 ± 0.08) and impact on HRQoL (? 0.04 ± 0.04) (Fig. 2a) . Inclusion of the modulating criteria in the participants' assessment increased the group's overall RBRB to ? 0.50 ± 0.14 ( Considering a potential choice between the SSA therapies (lanreotide and octreotide), the majority of criteria did not favor either option (data not shown), with a mean RBRB (? 0.07 ± 0.12, range -0.04 to ? 0.31) and a modulated RBRB (? 0.10 ± 0.10, range -0.04 to ? 0.32), slightly favoring lanreotide. Impact on autonomy contributed most to the RBRB (? 0.06 ± 0.06) and quality of evidence to the modulated RBRB (? 0.03 ± 0.05).
Face Validity and Impact of the Weighting Method
Seven patients and clinicians responded to the post-workshop face validity exercise; all confirmed that the visual representation of their weights and RBRBs reflected their thinking. Group-level RBRBs that incorporated weights elicited using the alternative weighting method (DRS) were similar to the RBRBs that incorporated weights elicited using the primary method (HPA) ( Table 2) . On an individual level, RBRBs elicited using the two methods differed by less than 0.10 points (on a scale of -1 to ? 1) for over 80% of participants and by less than 0.05 points for 45% to 63% of participants, depending on scenario and type of RBRB.
Exploratory Comparison with US Study Findings
Overall, mean weights and scores were similar between patients and clinicians participating in the Spanish and the US studies (Figs. 3, 4) ; nevertheless, specific differences were noted: Spanish participants tended to assign higher weights to the comparative patient-perceived health/PROs (and its subcriteria), type of therapeutic benefit, and system capacity and appropriate use at the expense of comparative efficacy/effectiveness and comparative safety/tolerability. Furthermore, compared to the US study, Spanish participants tended to score several criteria (and subcriteria) more in favor of treatment (positive scores), including convenience/ease of use/mode and setting of administration, comparative safety/tolerability, and the economic (sub)criteria, especially the cost to patient (Spain ? 2.5 ± 2.7 vs USA -2.8 ± 1.8) and the cost and constraints to patient (? 1.4 ± 2.3 vs -1.2 ± 1.3).
Numerically, both the RBRB and the modulated RBRB were larger in the Spanish than in the US study (RBRB ? 0.32 ± 0.24 vs ? 0.18 ± 0.20; modulated RBRB ? 0.50 ± 0.14 vs ? 0.29 ± 0.28), but all favored treatment over watchful waiting. The single largest contributor to the RBRB was progression-free survival in both studies (? 0.11 and ? 0.12). Two of the top three largest contributors to the modulated RBRB were the same in both studies (type of therapeutic benefit and disease severity); the remaining (quality of evidence) ranked fourth in the US study and (comparative efficacy/effectiveness) fifth in the Spanish study.
DISCUSSION
In this study, Spanish patients and clinicians explored what matters to them and how it matters when considering and deciding on the treatment options for unresectable, well-differentiated nonfunctioning GEP-NET, on the basis of a previously developed reflective MCDA decision support framework, which has been adapted to the Spanish context.
The weighting exercise indicated that most criteria of the framework had at least some importance for GEP-NET decision-making for a majority of Spanish patients and clinicians, thus confirming their relevance for patients and clinicians facing the same clinical situation across different countries. The relative weights assigned across the core benefit-risk criteria revealed the critical role of patient-perceived health/PRO outcomes for the Spanish participants, particularly the patient subgroup, who allocated more weight to impact on health-related HRQoL (0.15 ± 0.06) and impact on autonomy (0.12 ± 0.06) than to any other outcome. In contrast, clinicians tended to assign lesser importance to impact on autonomy (0.07 ± 0.03) and more to overall survival (0.14 ± 0.07 vs 0.10 ± 0.06). Although these differences should be interpreted with caution as the study was not designed to derive valid comparisons between patients and clinicians, they do highlight the need for effective patient-physician communication to incorporate patients' individual priorities in decisionmaking [18] . Non-fatal non-serious adverse events and non-fatal serious adverse events received comparatively small weights, indicating willingness to trade non-life-threatening risks and moderate side effects for improved quality of life and survival, as was also observed in previous studies [19] [20] [21] . Type of therapeutic benefit, quality of evidence, and disease severity figured among the highest weighted modulating criteria, confirming the importance of these considerations for decision-making. Disease severity and type of therapeutic benefit were also among the top three modulating criteria in the US study [12] . Nevertheless, large variability in weights was observed, reflecting differences in individual value systems.
System capacity and appropriate use also figured among the most important criteria based on HPA weighting. However, this criterion ranked only 8th in weight (among 14 criteria) when using the alternative weighting method, DRS, which largely confirmed the HPA-derived ranking of the other criteria. Using the hierarchical weighting method (HPA), participants had to assign a weight to the feasibility domain relative to other domains of the modulated benefit-risk tree; however, system capacity and appropriate use was the only criterion under the domain feasibility. In contrast, domains were not weighted using the nonhierarchical DRS method, which assigns weights at the criteria level only. These differences may explain the discrepancies in the weights for system capacity and appropriate use derived from the two methods. Each weight elicitation method stimulates a slightly different thinking pathway [16] (e.g., in this case, the HPA method prompted reflection on the importance of feasibility as a concept), and therefore weights are expected to vary across methods. The effect of the weight elicitation method on value assessment was previously explored and demonstrated minor impact at the group level [16] . This was confirmed in this study, which showed good agreements of RBRBs derived using the two weighting techniques on the group level and good agreements at the individual level. Previous research has also demonstrated reproducibility of DRS weights at the individual level [15] . Fig. 2 Mean RBRB contributions* of each quantitative criterion and overall RBRB for treatment (using lanreotide as reference case) versus watchful waiting a core benefit-risk model, b modulated benefit-risk model. *Values shown represent the contribution of criteria to the relative benefit-risk balance calculated as normalized weight (summing to 1) multiplied by score for each criterion (theoretical range from -1 to ? 1). Relative benefit-risk balance is the sum of contributions from all criteria (theoretical range from -1 to ? 1). Error bars show standard deviations across 11 participants Using the scoring exercise, patients and clinicians expressed their views on how each criterion favored one or other management option, on the basis of the available evidence and their own knowledge, and shared their insights with others. Similar to their US counterparts, Spanish patients and clinicians viewed impact on progression-free survival, disease severity, quality of evidence, and type of therapeutic benefit consistently in favor of SSA treatment. Large variations in scores indicated areas where individual perspectives diverged and/or where evidence was limited or inconclusive. For example, for comparative safety/tolerability outcomes, safety data from a double-blind study was available [22] , but its interpretation with respect to decision-making differed significantly among individuals and subgroups. Patients as a subgroup deemed non-serious and non-fatal serious adverse events in favor of watchful waiting, whereas physicians viewed them in favor of treatment, pointing out that treatment side effects were transient and mild in nature.
Overall, combination of all quantitatively considered decision criteria, weighted by their importance, favored SSA treatment over watchful waiting, especially when all factors that modulated the relative benefit-risk balance (RBRB) were incorporated; however, the strength of the preference for treatment varied among individuals. Some qualitatively considered criteria also impacted the decision-making. The relative consistency between the findings of the current and the US study in terms of criteria weights, scores, and RBRBs validates the applicability of the approach across different settings. Nevertheless, the approach was also able to capture specific differences that are possibly related to cultural and healthcare system aspects. These include the importance of the concept of autonomy to Spanish patients as well as differences in the costs to patients between the Spanish and the US context. In the Spanish universal healthcare system, SSAs are classified under ''Medicamentos y productos sanitarios de 'Aportació n Reducida'' [23, 24] , for which patients pay a maximum monthly of €4.24 per prescription. In contrast, in the US healthcare system, depending on type of insurance, patients may have to contribute a copayment of 20% [25] , which could amount to over $14,000 annually for SSA therapy [12] . RBRBs and modulated RBRBs can range from -1 to ? 1. N = 11 participants DRS direct weighting scale, HPA hierarchical point allocation, RBRB relative benefit-risk balance, SD standard deviation
The overall feedback on the process was that the exercise was helpful to understand (''empathize with'') the point of view of those with different perspectives and thus the approach could have a role in supporting patient-clinician communication. Participants also noted Fig. 3 Comparison of normalized weights from US and Spanish study participants* for the (sub)criteria of the a core and b the modulated benefit-risk tree. *5 patients and 6 clinicians participated in each study. Error bars represent the standard error of the mean Fig. 4 Comparison of scores from US and Spanish study participants for the a benefit-risk intervention outcomes criteria and b the modulating criteria. *5 patients and 6 clinicians participated in each study. Error bars represent the standard error of the mean that the experience helped them realize the role of uncertainty in decision-making as well as the breadth of different aspects that can weigh on the decision and the challenge of balancing these considerations.
This study has a number of limitations, some of which have been highlighted by the participants and could be addressed in future research. Non-functioning GEP-NETs are heterogeneous in symptoms and prognosis [5] . Specifically, tumors of pancreatic and of intestinal origin may have distinct management implications and could have been explored separately [5] . Furthermore, although the language in the evidence matrix has been adapted, some patients commented that technical terms relating to clinical evidence were not always easy to understand, thus suggesting a need for additional efforts to convey technical information in more accessible language. An additional limitation was that the scoring scale, ranging from -5 to ? 5, may have subconsciously created a negative perception of the option that was associated with the negative score, which could be addressed by a different scale design. In this study, a reference case approach was used to explore the primary decision scenario, i.e., whether to start SSA therapy or to monitor the disease (watchful waiting), with lanreotide used as the reference SSA. Alternatively, the primary decision scenario could have been explored in a more comprehensive approach based on the data available for all SSAs; however, for certain clinical decision criteria, this would have doubled the amount of data to be considered by the participants during the workshop, while likely resulting in similar assessments as the reference case approach.
CONCLUSION
By providing a common platform to consider the wide range of factors that may impact a decision, the approach helped Spanish patients and clinicians identify and express what matters to them. Comparison with US study findings confirmed the transferability of the approach. This decision framework thus can be translated into a decision tool for supporting patient-clinician communication on individual values, preferences, and judgements, which extends beyond clinical factors and can be adapted to different decision-making contexts. Similar reflective multicriteria approaches could also be useful to collect stakeholder inputs for other applications, such as to inform clinical trial design or reimbursement decision-making.
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